Carfilzomib, lenalidomide, and dexamethasone improved progression-free survival (PFS) over... The ORR was 96%, including 92% at the level of VGPR, and the MRD negativity rate was 62%... However, the three-drug combination improved survival in the relapsed/refractory setting.